• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Pulmonx Corporation

    11/24/25 4:11:30 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care
    Get the next $LUNG alert in real time by email
    S-8 1 pulmonx-sx8x11242025.htm S-8 Document

    As filed with the U.S. Securities and Exchange Commission on November 24, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    Pulmonx Corporation
    (Exact name of Registrant as specified in its charter)
    Delaware77-0424412
    (State or other jurisdiction of
    Incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    700 Chesapeake Drive
    Redwood City, California 94063
    (650) 364-0400
    (Address of principal executive offices) (Zip code)

    Pulmonx Corporation 2025 Inducement Plan
    (Full titles of the plans)

    David Lehman
    General Counsel
    Pulmonx Corporation
    700 Chesapeake Drive
    Redwood City, California 94063
    (650) 364-0400
    (Name, address and telephone number, including area code, of agent for service)
    Copies to:
    John T. McKenna
    Cooley LLP
    3175 Hanover Street
    Palo Alto, California 94304
    (650) 843-5000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☐
    Non-accelerated filer☒Smaller reporting company☒
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE
    Pulmonx Corporation (the “Registrant”) is filing this registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) for the purpose of registering 3,200,000 shares of its common stock, par value $0.001 per share (the “Common Stock”) reserved and available for issuance under the Registrant's 2025 Inducement Plan (the “Plan”).

    On November 21, 2025, the Registrant’s board of directors adopted the Plan, pursuant to which the Registrant reserved 3,200,000 shares of its Common Stock to be used exclusively for grants of equity-based awards to eligible individuals, as an inducement material to such individual’s entry into employment with the Registrant or any of its affiliates within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The Plan was adopted by the Registrant’s Compensation Committee of the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.


    PART I
    INFORMATION REQUIRED IN THE
    SECTION 10(a) PROSPECTUS

    Information required by Part I of Form S-8 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). The document(s) containing the information specified in Part I will be delivered to the participants in the Plan, as required by Rule 428(b)(1). Such document(s) are not being filed with the SEC as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These document(s) and the documents incorporated by reference in the Registration Statement pursuant to Item 3 of Part II of this form, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    ITEM 3.   INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the SEC are incorporated by reference into this Registration Statement (other than information in such filings deemed, under SEC rules, not to have been filed with the SEC):

    (a)the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025 (the “2024 10-K”);

    (b)the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 8, 2025 (but only with respect to information specifically incorporated by reference into the 2024 10-K);

    (c)the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, June 30, 2025, and September 30, 2025, filed with the SEC on May 2, 2025, August 1, 2025, and November 12, 2025, respectively;

    (d)the Registrant’s Current Reports on Form 8-K, filed with the SEC on May 23, 2025 and October 27, 2025 (but not the information furnished under Item 2.02 on a Current Report on Form 8-K filed October 27, 2025); and

    (e)the description of the Registrant’s Common Stock which is contained in a registration statement on Form 8-A filed on September 24, 2020 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 15, 2021.





    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    ITEM 4. DESCRIPTION OF SECURITIES

    Not applicable.

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

    Not applicable.

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

    Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit, or proceeding to which such person is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue, or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    As permitted by the Delaware General Corporation Law, the Registrant’s amended and restated certificate of incorporation permits indemnification of its directors, officers, and agents to the fullest extent permitted by applicable law, and the Registrant’s amended and restated bylaws provide that: (1) the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law; (2) the Registrant may, in its discretion, indemnify its other officers, employees, and agents as set forth in the Delaware General Corporation Law; (3) the Registrant is required, upon satisfaction of certain conditions, to advance all expenses incurred by its directors and executive officers in connection with certain legal proceedings; and (4) the rights conferred in the amended and restated bylaws are not exclusive.

    The Registrant’s policy is to enter into agreements with its directors that require it to indemnify them against expenses, judgments, fines, settlements, and other amounts that any such person becomes legally obligated to pay (including with respect to a derivative action) in connection with any proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that such person is or was a director of the Registrant or any of its affiliates, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the Registrant’s best interests. These indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder. At present, no litigation or proceeding is pending that involves any of its directors regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.




    The Registrant maintains a directors’ and officers’ liability insurance policy. The policy insures directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses the Registrant for those losses for which it has lawfully indemnified the directors and officers. The policy contains various exclusions.

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED

    Not applicable.



    ITEM 8.    EXHIBITS
    The exhibits to this Registration Statement are listed below:
    Incorporated by Reference
    Exhibit
    Number
    Description
    Schedule
    Form
    File NumberExhibitFiling Date
    4.1
    Amended and Restated Certificate of Incorporation of the Registrant.
    8-K001-395623.1October 5, 2020
    4.2
    Amended and Restated Bylaws of the Registrant.
    S-1/A333-2486353.4September 24, 2020
    4.3
    Form of Common Stock Certificate of the Registrant.
    S-1/A333-2486354.1September 24, 2020
    5.1*
    Opinion of Cooley LLP.
    23.1*
    Consent of Cooley LLP (included in Exhibit 5.1).
    23.2*
    Consent of BDO USA, P.C., independent registered public accounting firm.
    24.1*
    Power of Attorney (included on the signature page of this Form S-8).
    99.1*
    Pulmonx Corporation 2025 Inducement Plan.
    107*
    Filing Fee Table.
    * Filed herewith
    ITEM 9. UNDERTAKINGS

    1.The undersigned registrant hereby undertakes:

    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

    (b) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.




    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.




    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, State of California, on November 24, 2025.

    PULMONX CORPORATION
    By:/s/ Glendon E. French
    Name:
    Glendon E. French
    Title:President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Glendon E. French and Derrick Sung, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ Glendon E. FrenchPresident, Chief Executive Officer and DirectorNovember 24, 2025
    Glendon E. French
    (Principal Executive Officer)
    /s/ Derrick SungChief Financial OfficerNovember 24, 2025
    Derrick Sung(Principal Financial Officer and Principal Accounting Officer)
    /s/ Thomas W. BurnsDirectorNovember 24, 2025
    Thomas W. Burns
    /s/ Richard FerrariDirectorNovember 24, 2025
    Richard Ferrari
    /s/ Daniel P. FlorinDirectorNovember 24, 2025
    Daniel Florin
    /s/ Georgia Garinois-MelenikiotouDirectorNovember 24, 2025
    Georgia Garinois-Melenikiotou
    /s/ Dana G. Mead, Jr.DirectorNovember 24, 2025
    Dana G. Mead, Jr.
    /s/ Tiffany SullivanDirectorNovember 24, 2025
    Tiffany Sullivan

    Get the next $LUNG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LUNG

    DatePrice TargetRatingAnalyst
    7/31/2025$2.50Overweight → Neutral
    Piper Sandler
    3/10/2025$17.00Buy
    D. Boral Capital
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    6/4/2024$12.00Buy
    Lake Street
    2/23/2024$16.00 → $14.00Overweight → Equal Weight
    Wells Fargo
    9/5/2023$18.00Buy
    Craig Hallum
    2/27/2023$10.00 → $15.00Equal Weight → Overweight
    Wells Fargo
    1/3/2023$8.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Sung Derrick claimed ownership of 135,319 shares (SEC Form 3)

    3 - Pulmonx Corp (0001127537) (Issuer)

    11/10/25 5:42:26 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Williamson Steven S. sold $15,437 worth of shares (9,648 units at $1.60), decreasing direct ownership by 3% to 358,967 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    9/3/25 5:14:06 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer & PAO Joshi Mehul sold $12,698 worth of shares (7,936 units at $1.60), decreasing direct ownership by 4% to 208,489 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    9/3/25 5:12:42 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Florin Daniel P bought $71,362 worth of shares (23,321 units at $3.06), increasing direct ownership by 25% to 117,231 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/5/25 8:39:08 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    8/22/24 6:41:17 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    SEC Filings

    View All

    SEC Form EFFECT filed by Pulmonx Corporation

    EFFECT - Pulmonx Corp (0001127537) (Filer)

    11/26/25 12:15:22 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form S-3/A filed by Pulmonx Corporation

    S-3/A - Pulmonx Corp (0001127537) (Filer)

    11/24/25 4:33:39 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Pulmonx Corporation

    S-8 - Pulmonx Corp (0001127537) (Filer)

    11/24/25 4:11:30 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pulmonx Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in international revenue in the third quarter of 2025, representing 15% year-over-year growth and an increase of 9% on a constant currency basisDelivered $14.0 million in U.S. revenue in the third quarter of 20

    11/12/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

    Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial OfficerSteve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediatelyPreliminary, unaudited third quarter 2025 revenue expected to be approximately $21.5 millionThird quarter 2025 financial results rescheduled to be released after the close of trading on Wednesday, November 12, 2025; Management to host conference call to discuss the results and the transition at 1:30 p.m. PT / 4:30 p.m.

    10/27/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025

    REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a

    10/15/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Pulmonx from Overweight to Neutral and set a new price target of $2.50

    7/31/25 7:16:23 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on Pulmonx with a new price target

    D. Boral Capital initiated coverage of Pulmonx with a rating of Buy and set a new price target of $17.00

    3/10/25 8:07:21 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx downgraded by Citigroup with a new price target

    Citigroup downgraded Pulmonx from Buy to Neutral and set a new price target of $7.50 from $17.00 previously

    12/11/24 7:54:19 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    Leadership Updates

    Live Leadership Updates

    View All

    Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

    REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

    4/2/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

    REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

    2/21/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

    LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir

    12/11/23 9:00:00 AM ET
    $HNST
    $LUNG
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    $LUNG
    Financials

    Live finance-specific insights

    View All

    Pulmonx Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in international revenue in the third quarter of 2025, representing 15% year-over-year growth and an increase of 9% on a constant currency basisDelivered $14.0 million in U.S. revenue in the third quarter of 20

    11/12/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

    Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial OfficerSteve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediatelyPreliminary, unaudited third quarter 2025 revenue expected to be approximately $21.5 millionThird quarter 2025 financial results rescheduled to be released after the close of trading on Wednesday, November 12, 2025; Management to host conference call to discuss the results and the transition at 1:30 p.m. PT / 4:30 p.m.

    10/27/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025

    REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a

    10/15/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/14/24 7:47:49 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/12/24 10:34:16 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/8/24 10:35:45 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care